Literature DB >> 1875788

The treatment of late luteal phase dysphoric disorder.

S Steinberg1.   

Abstract

This mini-review provides a comprehensive discussion of the management of the late luteal phase dysphoric disorder (LLPDD). The various treatments will be described with particular attention to their efficacy and the nature of side effects. These include: psychoactive drugs (lithium, anxiolytics, antidepressants), nutritional agents (L-tryptophan, Vitamin B6, prostaglandins precursors and inhibitors), dopamine agonists, diuretics, antihypertensives, hormonal interventions (gonadotrophin releasing hormone analogues, oestradiol, tamoxifen, progesterone, danazol, and oral contraceptives). Less attention has been given to non-pharmacologic approaches such as diet, exercise and psychotherapy. The availability of an operational definition of LLPDD in the DSM-III-R and the improvement in research methodology has provided a clearer direction for clinical management and for future investigations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1875788     DOI: 10.1016/0024-3205(91)90244-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Fluoxetine treatment of severe premenstrual syndrome.

Authors:  D B Menkes; E Taghavi; P A Mason; G F Spears; R C Howard
Journal:  BMJ       Date:  1992-08-08

2.  Tryptophan in the treatment of late luteal phase dysphoric disorder: a pilot study.

Authors:  S Steinberg; L Annable; S N Young; M C Bélanger
Journal:  J Psychiatry Neurosci       Date:  1994-03       Impact factor: 6.186

Review 3.  Comorbid Premenstrual Dysphoric Disorder in Women with Bipolar Disorder: Management Challenges.

Authors:  Gianna Sepede; Marcella Brunetti; Massimo Di Giannantonio
Journal:  Neuropsychiatr Dis Treat       Date:  2020-02-10       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.